Monday, Human Genome Sciences Inc. (HGSI) appointed Scott Habig as Vice President of Sales. Habig was most recently Vice President, Sales, at Centocor Ortho Biotech, a subsidiary of Johnson & Johnson.
During his nine years with the Centocor and Centocor Ortho Biotech subsidiaries of Johnson & Johnson, Habig held a number of key leadership positions, including Vice President, Sales and Marketing. He developed and led the execution of sales and marketing strategy that established REMICADE as a leading product for the treatment of autoimmune diseases including Crohn's disease, rheumatoid arthritis, psoriasis and ulcerative colitis.
Human Genome Sciences Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.